Oct. 22 at 6:17 PM
$SCNX One lesser-highlighted strength of the TWO FDA APPROVALS :
1- Arbli &
2- Rezenopy
1. The company’s first-to-market position with its liquid formulation of losartan (Arbli™) gives it a unique niche in hypertension treatment. Many patients struggle with tablets (due to swallowing difficulties, pediatrics, geriatrics), so a ready-to-use liquid opens a differentiator. That niche can translate into premium pricing and formulary leverage (once positioned). Since they have the first mover advantage in that format, competitors may face higher hurdles to catch up.
2. Also, securing the exclusive U.S. rights to the opioid overdose rescue product (REZENOPY®) puts them into a
$1.5B plus market (as previously noted). That gives a two-legged platform (cardio-liquid + rescue/emergency) which allows cross-leverage of commercial infrastructure, distribution, and formulary relationships.
$DRUG
